BioSpace News Archive

Akebia Therapeutics, Inc. today announced plans to release its financial results for the fourth quarter and full-year ended December 30, 2022 on Thursday, March 9.

Silence Therapeutics plc today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2022, on Wednesday, March 15, 2023.

HeartBeam, Inc anywhere, will hold a conference call on Thursday March 16, 2023 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2023 milestones.

Vistagen today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Cowen 43rd Annual Health Care Conference.

Neuro20 Technologies Corp today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s 510(k) pre-market approval application for its Neuro20 PRO System.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing enhancements to its cardiology portfolio at the Annual Scientific Session & Expo of the American College of Cardiology/World Congress of Cardiology event (ACC.23/WCC, March 4 – 6, New Orleans, USA).

Axis Research & Technologies, a premier bioskills training and cadaver lab supporting medical device research and training, is proud to introduce Dr. Mark G. Freeman as the company’s Chief Medical Advisor.

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Officer effective February 24, 2023.

Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, was recently awarded a grant from Israel’s Ministry of Economy to encourage the Company’s marketing activities and enhance the commercialization of the LIBERTY Robotic System in the US market, within the scope of its ‘Smart Money’ program.

Debiopharm (www.debiopharm.com) today announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk.